Results 251 to 260 of about 545,624 (314)

Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available - Practical Dose Selection Considerations and Real-World Access Challenges. [PDF]

Lung Cancer (Auckl)
Aldecoa KAT, Arter ZL, Ou SI, Nagasaka M.   +3 more
europepmc   +1 more source

Effect of prior anti-EGFR therapy and baseline ctDNA profiling on the efficacy of pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer: an integrated analysis of TRIUMPH/MyPathway. [PDF]

ESMO Open
Matsubara Y, Wakabayashi M, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Masuishi T, Nishina T, Bando H, Misumi T, Fukui M, Matsuda S, Ikeda Y, Malato J, Schulze K, Price R, Sato A, Yoshino T, Nakamura Y.   +19 more
europepmc   +1 more source

Dacomitinib for EGFR-L858R-mutated non-small cell lung cancer following acquired resistance to third-generation EGFR-TKIs: a retrospective real-world study. [PDF]

Transl Lung Cancer Res
Wang Q, Yin X, Zhao K, Li Y, Kong L, Jiang L, Zhao H, Wang X, Li X, Chen Y, Meng X.   +10 more
europepmc   +1 more source

Mechanism of afatinib resistance in non-small cell lung cancer patients with nonclassical EGFR mutations: A multicenter, retrospective study. [PDF]

Medicine (Baltimore)
Wu R, Fang S, Zhang Y, Zhou T, Yin J, Yao Y, Ding M, Ding H, Wang J, Zhang Q, Liu H.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

EGFR and anti-EGFR nanobodies: review and update

Journal of Drug Targeting, 2020
Targeted therapy is one of the favourable methods used in cancer treatment. Several recombinant proteins and small-molecules used for this aim include monoclonal antibodies, antibody fragments and peptides. Nanobody (Nb) is a camelid antibody fragment that is very effective in targeted therapy.
Jafar Sharifi, Mohammad Reza Khirehgesh, Fatemeh Safari, Bahman Akbari   +3 more
openaire   +2 more sources

EGFR Aggregation in the Brain

ACS Chemical Neuroscience, 2021
Recent findings showed that preformed fibrils (PFFs) of misfolded proteins, including α-synuclein (α-syn) and amyloid-β (Aβ), activate EGFR in cell cultures and animal models of amyloid propagation. Comparing these supramolecular structures to normal EGFR ligands such as EGF and HB-EGF suggests that these PFFs might trigger the formation of high order ...
Omid Tavassoly, Iman Tavassoly
openaire   +2 more sources

Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.

Current Topics in Medicinal Chemistry, 2020
The epidermal growth factor receptor (EGFR) belongs to ERBB family of tyrosine kinase receptor. EGFR signaling cascade is a key regulator in cell proliferation, differentiation, division, survival, and cancer development.
D. Sabbah, Rima Hajjo, K. Sweidan
semanticscholar   +1 more source

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

The Lancet Respiratory Medicine, 2019
BACKGROUND The IMpower150 trial showed significant improvements in progression-free and overall survival with atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) versus the standard-of-care bevacizumab plus carboplatin plus paclitaxel ...
M. Reck, T. Mok, M. Nishio, R. Jotte, F. Cappuzzo, F. Orlandi, D. Stroyakovskiy, N. Nogami, D. Rodríguez-Abreu, D. Moro-Sibilot, C. Thomas, F. Barlesi, G. Finley, Anthony Lee, S. Coleman, Yu Deng, M. Kowanetz, G. Shankar, W. Lin, M. Socinski   +19 more
semanticscholar   +1 more source

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet Oncology, 2019
BACKGROUND Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the approach is not widely implemented.
K. Nakagawa, E. Garon, T. Seto, M. Nishio, S. Ponce Aix, L. Paz-Ares, C. Chiu, Keunchil Park, S. Novello, E. Nadal, F. Imamura, K. Yoh, J. Shih, K. Au, D. Moro-Sibilot, S. Enatsu, A. Zimmermann, B. Frimodt-Moller, C. Visseren-Grul, M. Reck   +19 more
semanticscholar   +1 more source